Sara Blum Sherman

Sara Blum Sherman currently serves as Vice President of Investor Relations at Recursion since November 2024, following a similar role at Exscientia from August 2021 to November 2024. Prior to that, UroGen Pharma employed Sara as Head of Investor Relations from September 2020 to August 2021. A substantial portion of Sara's career was spent at DBV Technologies, where roles included Senior Director of Global Medical Strategy & Operations and Senior Director of Investor Relations & Strategy, among others, from August 2016 to September 2020. Earlier experience at Bank of America Merrill Lynch involved positions as Equity Research Associate and Analyst from November 2011 to June 2016, as well as Treasury Analyst from June 2010 to October 2011. Initial exposure to the finance industry came through an internship at Bloomberg Tradebook in 2009. Sara holds a degree from Northwestern University and completed earlier education at Horace Mann School.